-
University of Hong Kong develops vaccine against H7N9 avian influenza
Time of Update: 2020-06-15
Business Agency, April 2 (Xinhua) -- Chinese mainland and Hong Kong have many people infected with H7N9 avian influenza, the University of Hong Kong research team said, successfully developed a vacci
-
Weekly Statement: An Analysis of the Protection Boundary of Pharmaceutical Patent Rights and Related Recommendations
Time of Update: 2020-06-12
Original title: "Weekly Statement" A brief review of the protection boundary of pharmaceutical patent rights and related proposals to analyze the protection boundary of pharmaceutical patent rights an
-
FDA has accepted a license for complementary biological products from Mercadon Gardasil 9
Time of Update: 2020-06-11
recently, the U.S Pharmaceutical sand announced that the U.S Food and Drug ( FDA ) has accepted a supplementary biologics license (sBLA) for the Gardasil 9 (Plus, 9-price recombinant human papi
-
New vaccine combined with existing immunotherapy could effectively fight melanoma, study finds
Time of Update: 2020-06-11
recently, researchers from the Sprees Institute in San Diego, in collaboration with experts from other institutions, have developed a new vaccine that, in combination with existing immunotherapy tre
-
FDA accepts new drug application from Roche Hemlibra ® (emicizumab-kxwh)
Time of Update: 2020-06-11
recentdays, Roche Pharmaceutical (announced that the U.S FDA (which has accepted the Hemlibra ® (emicizumab-kxwh) for the treatment of adults and children with no type 8 factor inhibitor, hemoph
-
FDA announces approval of Shionogi's new drug Mulpleta (lusutrombopag) to market
Time of Update: 2020-06-11
Today, the U.S FDA announced the approval of Shionogi's new drug to treat specific groups of adult patients with thrombocytopenia These patients also suffer from chronic liver disease and have p
-
FDA approves first monthly injection of leppenketone long-acting needle to be available for treatment of adult schizophrenia
Time of Update: 2020-06-11
recently, the U.S Food and Medicines ( FDA approved the first monthly injection of Perseris, Indivior, for the treatment of adult schizophrenia manufacturers of (it is noted that, by using a
-
Hao Ding biotech anti-cancer new drug OBI-3424 obtains FDA-issued orphan drug qualification
Time of Update: 2020-06-11
HCC is the sixth-largest cancer in the world, but it is rare in the United States, with about 61,483 cases in 2018 HCC is a deadly cancer with a five-year survival rate of 12.2%, the third leading c
-
Gilead's Ekoun tablets used to treat HIV-1 infection are approved in China
Time of Update: 2020-06-11
recently, Gilead Science s (announced that the National Drug (the Supervisory Authority approved the use of Jetcon (Ecoon tablets, or E/C/F/TAF) to treat HIV-1 infection in China, Jetkang is a
-
EMA grants chikungunya vaccine program priority drug eligibility
Time of Update: 2020-06-11
chikungunya fever is an acute infectious disease caused by CHIKV, transmitted by the Aedes aegypti mosquito, characterized by fever, rash and joint pain, with long-term debilitating effects, and the
-
LYNPARZA for pancreatic cancer treatment obtains FDA-granted orphanage drug designation
Time of Update: 2020-06-11
pancreatic cancer is a rare, life-threatening disease that accounts for about 3% of all cancers in the United States Due to the late onset of symptoms, patients are usually diagnosed only after the
-
FDA accepts biologics license application for PNH in research drug ALXN1210
Time of Update: 2020-06-11
recently, Alexion Pharmaceuticals that the FDA , , has accept ed an application for a biological license (BLA) for the of the drug , the Ravulizumab, for a valiant sleeping hemoglobinuria (PNH)
-
The State Drug Administration has approved Sanofifashuk for uric acid control in children with leukemia and lymphoma
Time of Update: 2020-06-11
recently, Sanofi China announced that the National Drug (The Supervisory Authority has recently approved Faschuk (injection with Labrihai) for children with leukemia, lymphoma patients with urinar
-
Clinical Phase 2 study data for the treatment of child growth hormone deficiency published by Novo nornod
Time of Update: 2020-06-11
recently, Novo Nordisk released clinical Phase 2 study data for the treatment of childhood growth hormone deficiency, showing that it has the same effect as the company's ( -day drug (® (®, growt
-
FDA provisionally approves Bryhali for treatment of plaque-type psoriasis in adult patients
Time of Update: 2020-06-11
recently, Bausch Health (and its dermatology company, Ortho Dermatologics) jointly announced that the U.S FDA (provisionally approved Brybetasol propionate, 0.01%) emulsion as a local treatment
-
The application for the listing of Ravidawe, a hepatitis C innovative drug, was accepted by the State Drug Administration
Time of Update: 2020-06-11
recently, the , The of the Limited Company (Co., Inc.), announced that its second new hepatitis C (Ravidasvir, RDV) as the future pan-genotype direct antiviral drug (DAA) was included in the l
-
FDA has granted GeneTek Xolair ® breakthrough therapy to identify foreheads to prevent food allergies
Time of Update: 2020-06-11
recently, Roche's GeneTek announced that the U.S fda (which has granted Xolair ® (omalizumab, Omazumab) breakthrough therapy to prevent accidental exposure to one or more foods can lead to severe
-
Gene Tektronix's new heavy flu drug Baloxavir marboxil's Phase 3 study CAPSTONE-2 reaches its main destination
Time of Update: 2020-06-11
today, Genentech, a member of the Roche Group, announced that the , a new drug to assess the efficacy of a new drug heavy influenza, reached its main destination in the phase 3 study CAPSTONE-2, wh
-
FDA accepts New Drug Listing Application for Gilteritinib for AML Adult Patient Treatment
Time of Update: 2020-06-11
acute myeloid leukemia (AML) is a blood malignant tumor with abnormal proliferation of bone marrow hematopoietic bud cells, and is the most common acute leukemia in adults , Japan's Astellas Pharma
-
FDA accepts new drug application from Shire's Gattex
Time of Update: 2020-06-11
recently, the of the British Pharmaceuticals (The Company) ( the FDA ) has accepted the supplementary new drug (sNDA) for Gattex.com the sNDA application for approval to expand the indication